切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 180 -183. doi: 10.3877/cma.j.issn.1674-1366.2022.03.008

病例分析

地舒单抗导致颌骨骨坏死一例及文献复习
王明1,(), 陈萍2   
  1. 1. 天津合心口腔医院种植科,天津 300000;杭州美奥口腔,杭州 310000
    2. 杭州美奥口腔,杭州 310000
  • 收稿日期:2022-04-27 出版日期:2022-06-01
  • 通信作者: 王明

Osteonecrosis of jaw caused by denosumab: A case report and literature review

Ming Wang1,(), Ping Chen2   

  1. 1. Department of Dental Implant, Hexin Stomatological Hospital, Tianjin 300000, China; MYOUR Dental Hangzhou, Hangzhou 310000, China
    2. MYOUR Dental Hangzhou, Hangzhou 310000, China
  • Received:2022-04-27 Published:2022-06-01
  • Corresponding author: Ming Wang
引用本文:

王明, 陈萍. 地舒单抗导致颌骨骨坏死一例及文献复习[J]. 中华口腔医学研究杂志(电子版), 2022, 16(03): 180-183.

Ming Wang, Ping Chen. Osteonecrosis of jaw caused by denosumab: A case report and literature review[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(03): 180-183.

地舒单抗是一种全人源单克隆抗体(IgG2类),2010年首次在欧盟上市被批准用于治疗骨折高风险的绝经后女性和男性骨质疏松症,于2020年6月在我国获批上市用于治疗骨质疏松。我国临床工作者对地舒单抗的应用经验尚不多。国内目前尚未报道地舒单抗造成颌骨骨坏死的病例。本文介绍1例由地舒单抗引起的颌骨骨坏死病例报告,并进行文献复习,以供口腔临床医师参考。

Denosumab is an all human monoclonal antibody (IgG2) , which was first listed in the EU in 2010 approved for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures. It was approved to be listed in China in June 2020 for the treatment of osteoporosis, but the clinicians in China have little experience in the application of denosumab. At present, there is no report of osteonecrosis of jaw caused by denosumab in China. This paper introduces a case report of osteonecrosis of jaw caused by denosumab, and reviews the literature for the reference of oral clinicians.

图1 患者27拔除4个月后的锥形束CT(CBCT)影像 可见上颌窦内稍高密度影像、拔牙窝内低密度阴影。
图3 患者拔牙窝死骨组织病理切片(苏木精-伊红 低倍放大)3A:可见骨小梁组织增生伴灶状坏死;3B:可见少量死骨。
[1]
Marx RE. Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws:A growing epidemic[J]. J Oral Maxillofac Surg200361(9):1115-1117. DOI:10.1016/s0278-2391(03)00720-1.
[2]
Kendler DL, Cosman F, Stad RK,et al. Denosumab in the treatment of osteoporosis:10 years later:A narrative review[J]. Adv Ther202239(1):58-74. DOI:10.1007/s12325-021-01936-y.
[3]
Khan AA, Morrison A, Kendler DL,et al. Case-based review of osteonecrosis of the jaw(ONJ)and application of the international recommendations for management from the International Task Force on ONJ[J]. J Clin Densitom201720(1):8-24. DOI:10.1016/j.jocd.2016.09.005.
[4]
Ruggiero SL, Dodson TB, Fantasia J,et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw:2014 update[J]. J Oral Maxillofac Surg201472(10):1938-1956. DOI:10.1016/j.joms.2014.04.031.
[5]
Wick A, Bankosegger P, Otto S,et al. Risk factors associated with onset of medicationrelated osteonecrosis of the jaw in patients treated with denosumab[J]. Clin Oral Investig202226(3):2839-2852. DOI:10.1007/s00784-021-04261-4.
[6]
Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy[J]. Br J Oral Maxillofac Surg201048(3):221-223. DOI:10.1016/j.bjoms.2009.08.030.
[7]
Nakamura Y, Kikuiri T, Sugiyama T,et al. Anti-RANKL inhibits thymic function and causes DRONJ in mice[J]. Int J Dent2022:9299602. DOI:10.1155/2022/9299602.
[8]
Papapoulos S, Chapurlat R, Libanati C,et al. Five years of denosumab exposure in women with postmenopausal osteoporosis:Results from the first two years of the FREEDOM extension[J]. J Bone Miner Res201227(3):694-701. DOI:10.1002/jbmr.1479.
[9]
牛晓辉,刘巍峰.地舒单抗临床应用安全性的思考[J].中国骨与关节杂志20187(9):641-645. DOI:10.3969/j.issn.2095-252X.2018.09.001.
[10]
Aldhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw:A review[J]. Cureus202012(2):e6944. DOI:10.7759/cureus.6944.
[11]
Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw[J]. Med Oral Patol Oral Cir Bucal202025(1):e71-e83. DOI:10.4317/medoral.23191.
[12]
Mollica V, Nuvola G, Tassinari E. Bone targeting agents in patients with prostate cancer:General toxicities and osteonecrosis of the jaw[J]. Curr Oncol202229(3):1709-1722. DOI:10.3390/curroncol29030142.
[13]
杨涛,魏建华,雷德林,等.药物相关性颌骨坏死的研究进展[J].现代肿瘤医学202028(6):1039-1042. DOI:10.3969/j.issn.1672-4992.2020.06.038.
[14]
Soma T, Iwasaki R, Sato Y,et al. Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues,antiinfammatory agents or antibiotic[J]. Sci Rep202212(1):19. DOI:10.1038/s41598-021-03966-6.
[15]
Ali IE, Sumitaa Y. Medication-related osteonecrosis of the jaw:Prosthodontic considerations[J]. Jpn Dent Sci Rev202258:9-12. DOI:10.1016/j.jdsr.2021.11.005.
[1] 王岩, 马剑雄, 郎爽, 董本超, 田爱现, 李岩, 孙磊, 靳洪震, 卢斌, 王颖, 柏豪豪, 马信龙. 外泌体在骨质疏松症诊疗中应用的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(05): 673-678.
[2] 方心俞, 黄昌瑜, 胡洪新, 林溢铭, 陈旸, 张楠心, 张文明. 膝关节软骨下不全骨折的治疗选择与疗效分析[J]. 中华关节外科杂志(电子版), 2023, 17(04): 583-587.
[3] 杨霁, 黄顺梅, 王安鸽, 吴月, 杨云梅. 杭州地区老年人群中肌少症患病情况及其与骨质疏松症的相关性分析[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 207-210.
[4] 陆宜仙, 张震涛, 夏德萌, 王家林. 巨噬细胞极化在骨质疏松中调控作用及机制的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 538-541.
[5] 陆军帅, 高礼层, 王逸群, 徐小彬, 麻文谦, 朱玮. 活动型牛津膝单髁置换在膝关节自发性骨坏死治疗中的应用价值[J]. 中华损伤与修复杂志(电子版), 2023, 18(01): 39-46.
[6] 李圣鹏, 方爱蓝, 刘诗宁, 王丹, 刘湘奇. 下颌阻生第三磨牙拔除难度的预测因素与评估方法[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 441-445.
[7] 陈跃圻, 罗睿, 向涵, 余泳妍, 余挺. 骨质疏松症与牙周炎的因果关系:一项两样本孟德尔随机化研究[J]. 中华口腔医学研究杂志(电子版), 2023, 17(04): 292-298.
[8] 张晗之, 丁梦婷, 佘文珺, 焦婷. 骨髓增生异常综合征继发上颌骨坏死患者术后全数字化即刻赝复体制作[J]. 中华口腔医学研究杂志(电子版), 2023, 17(04): 253-259.
[9] 南方护骨联盟前列腺癌骨转移专家组. 前列腺癌骨转移诊疗专家共识(2023版)[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 201-208.
[10] 倪鑫淼, 王磊, 王潇, 陈志远, 翁小东, 刘修恒. 前列腺癌患者骨保护现状及临床用药进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 191-195.
[11] 张茜, 刘叶青, 康雪莹, 孙兵兵, 刘岩, 胡丽叶, 周亚茹. 血清铁蛋白与绝经后骨质疏松症的相关性分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(03): 166-171.
[12] 覃成禹, 周昊楠, 陈远明. 葛根素对绝经后骨质疏松大鼠不同部位骨骼的抗骨质疏松作用差异的研究[J]. 中华老年骨科与康复电子杂志, 2023, 09(01): 23-27.
[13] 许航, 崔宇韬, 任广凯, 刘贺, 王雁冰, 彭传刚, 吴丹凯. 骨质疏松症关键基因的筛选及生物信息学分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(01): 18-22.
[14] 张靖, 王奇. 一例下颌骨动静脉畸形的栓塞治疗[J]. 中华介入放射学电子杂志, 2023, 11(04): 392-392.
[15] 白晓辉, 张龙, 王永峰, 冯毅, 赵斌, 吕智, 徐朝健. 单侧与双侧经皮椎体成形术治疗Kummell病的疗效比较[J]. 中华老年病研究电子杂志, 2023, 10(02): 14-18.
阅读次数
全文


摘要